{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:56:18Z","timestamp":1759179378646,"version":"3.38.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To clarify whether alterations in midazolam pharmacokinetics resulting from changes in cytochrome P450 3A (CYP3A) activity lead to changes in its pharmacodynamic effects, benzodiazepine receptor occupancy was measured in the brain of rats after oral administration of midazolam.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Receptor occupancy was measured by radioligand binding assay in rats pretreated with ursodeoxycholic acid (UDCA), ketoconazole and dexamethasone, and the plasma concentration of midazolam was simultaneously determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key findings<\/jats:title><jats:p>There was a significant increase in the apparent dissociation constant and decrease in the maximum number of binding sites for specific [3H]flunitrazepam binding after oral administration of midazolam at pharmacologically relevant doses, suggesting that midazolam binds significantly to brain benzodiazepine receptors. Pretreatment with UDCA significantly enhanced the binding. This correlated well with significant enhancement by UDCA of the plasma midazolam concentration. The brain benzodiazepine receptor binding of oral midazolam was significantly enhanced by pretreatment with ketoconazole, a potent inhibitor of CYP3A, whereas it was significantly reduced by treatment with dexamethasone, an inducer of this enzyme. These effects paralleled changes in the plasma concentration of midazolam.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results indicate that pharmacokinetic changes such as altered CYP3A activity significantly influence the pharmacodynamic effect of midazolam by affecting occupancy of benzodiazepine receptors in the brain. They also suggest in-vivo or ex-vivo time-dependent measurements of receptor occupancy by radioligand binding assay to be a tool for elucidating the pharmacokinetic interaction of benzodiazepines with other agents in pre-clinical and clinical evaluations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.2042-7158.2010.01176.x","type":"journal-article","created":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T12:56:26Z","timestamp":1289912186000},"page":"58-64","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of the pharmacokinetic interaction of midazolam with ursodeoxycholic acid, ketoconazole and dexamethasone by brain benzodiazepine receptor occupancy"],"prefix":"10.1093","volume":"63","author":[{"given":"Shingen","family":"Misaka","sequence":"first","affiliation":[{"name":"Department of Pharmacokinetics and Pharmacodynamics, Global Center of Excellence (COE), Practical Pharmacy and Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka , Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souhei","family":"Kurosawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Pharmacodynamics, Global Center of Excellence (COE), Practical Pharmacy and Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka , Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Pharmacodynamics, Global Center of Excellence (COE), Practical Pharmacy and Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka , Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Pharmacodynamics, Global Center of Excellence (COE), Practical Pharmacy and Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka , Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Kato","sequence":"additional","affiliation":[{"name":"Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University , Tokushima,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Pharmacodynamics, Global Center of Excellence (COE), Practical Pharmacy and Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka , Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuo","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Pharmacodynamics, Global Center of Excellence (COE), Practical Pharmacy and Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka , Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,1,1]]},"reference":[{"key":"2024103013284438600_cit1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-198106060-00002","article-title":"Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models","volume":"6","author":"Holford","year":"1981","journal-title":"Clin Pharmacokinet"},{"key":"2024103013284438600_cit2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1054-3589(08)60658-4","article-title":"Pharmacology of benzodiazepines: laboratory and clinical correlations","volume":"5","author":"Zbinden","year":"1967","journal-title":"Adv Pharmacol"},{"key":"2024103013284438600_cit3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2165\/00003495-198428060-00002","article-title":"Midazolam. A review of its pharmacological properties and therapeutic use","volume":"28","author":"Dundee","year":"1984","journal-title":"Drugs"},{"key":"2024103013284438600_cit4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0026-895X(25)09118-7","article-title":"Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4","volume":"36","author":"Kronbach","year":"1989","journal-title":"Mol Pharmacol"},{"key":"2024103013284438600_cit5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0022-3565(25)12284-2","article-title":"Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole","volume":"276","author":"von Moltke","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"2024103013284438600_cit6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/00498250802621680","article-title":"Effect of ursodeoxycholic acid on the pharmacokinetics of midazolam and CYP3A in the liver and intestine of rats","volume":"39","author":"Kurosawa","year":"2009","journal-title":"Xenobiotica"},{"key":"2024103013284438600_cit7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/clpt.1993.25","article-title":"A potentially hazardous interaction between erythromycin and midazolam","volume":"53","author":"Olkkola","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"2024103013284438600_cit8","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1124\/jpet.102.035972","article-title":"In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat","volume":"302","author":"Kotegawa","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"2024103013284438600_cit9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1126\/science.918669","article-title":"Benzodiazepine receptor: demonstration in the central nervous system","volume":"198","author":"Mohler","year":"1977","journal-title":"Science"},{"key":"2024103013284438600_cit10","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/266732a0","article-title":"Benzodiazepine receptors in rat brain","volume":"266","author":"Squires","year":"1977","journal-title":"Nature"},{"key":"2024103013284438600_cit11","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/S0024-3205(98)00495-0","article-title":"Ex vivo occupancy by tamsulosin of alpha1-adrenoceptors in rat tissues in relation to the plasma concentration","volume":"63","author":"Ohkura","year":"1998","journal-title":"Life Sci"},{"key":"2024103013284438600_cit12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.bjp.0706184","article-title":"Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice","volume":"145","author":"Oki","year":"2005","journal-title":"Br J Pharmacol"},{"key":"2024103013284438600_cit13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0163-7258(94)00073-C","article-title":"Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children","volume":"66","author":"Poupon","year":"1995","journal-title":"Pharmacol Ther"},{"key":"2024103013284438600_cit14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/hep.510280601","article-title":"Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications","volume":"28","author":"Beuers","year":"1998","journal-title":"Hepatology"},{"key":"2024103013284438600_cit15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0889-8553(21)00539-2","article-title":"Treatment of cholesterol gallstones with litholytic bile acids","volume":"20","author":"Salen","year":"1991","journal-title":"Gastroenterol Clin North Am"},{"key":"2024103013284438600_cit16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1046\/j.1365-2036.1999.00596.x","article-title":"Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases","volume":"13","author":"Trauner","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"2024103013284438600_cit17","doi-asserted-by":"crossref","first-page":"39411","DOI":"10.1074\/jbc.M106340200","article-title":"Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450","volume":"276","author":"Schuetz","year":"2001","journal-title":"J Biol Chem"},{"key":"2024103013284438600_cit18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/jhep.2002.34939","article-title":"Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities","volume":"36","author":"Paolini","year":"2002","journal-title":"Hepatology"},{"key":"2024103013284438600_cit19","doi-asserted-by":"crossref","first-page":"38685","DOI":"10.1074\/jbc.M105127200","article-title":"Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4","volume":"276","author":"Bodin","year":"2001","journal-title":"J Biol Chem"},{"key":"2024103013284438600_cit20","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1023\/A:1018906614320","article-title":"Inhibition of human CYP3A catalyzed 1\u2032-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine","volume":"11","author":"Wrighton","year":"1994","journal-title":"Pharm Res"},{"key":"2024103013284438600_cit21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0026-895X(25)14931-6","article-title":"Immunochemical evidence for induction of a common form of hepatic cytochrome P-450 in rats treated with pregnenolone-16 alpha-carbonitrile or other steroidal or non-steroidal agents","volume":"21","author":"Heuman","year":"1982","journal-title":"Mol Pharmacol"},{"key":"2024103013284438600_cit22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/0024-3205(81)90744-X","article-title":"High affinity [3H]flunitrazepam binding: characterization, localization, and alteration in hypertension","volume":"28","author":"Regan","year":"1981","journal-title":"Life Sci"},{"key":"2024103013284438600_cit23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0378-4347(00)82020-4","article-title":"Determination of midazolam (Versed) and its metabolites in plasma by high-performance liquid chromatography","volume":"344","author":"Puglisi","year":"1985","journal-title":"J Chromatogr"},{"key":"2024103013284438600_cit24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/BF02439589","article-title":"Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity","volume":"93","author":"Arendt","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"2024103013284438600_cit25","first-page":"2180","article-title":"Pharmacology of midazolam","volume":"31","author":"Pieri","year":"1981","journal-title":"Arzneimittelforschung"},{"key":"2024103013284438600_cit26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/clpt.1992.84","article-title":"Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers","volume":"51","author":"Mandema","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"2024103013284438600_cit27","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/sj.bjp.0705371","article-title":"In vitro and ex vivo effects of a selective nociceptin\/orphanin FQ (N\/OFQ) peptide receptor antagonist, CompB, on specific binding of [3H]N\/OFQ and [35S]GTPgammaS in rat brain and spinal cord","volume":"139","author":"Yamada","year":"2003","journal-title":"Br J Pharmacol"},{"key":"2024103013284438600_cit28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2125.1990.tb03677.x","article-title":"The effect of food and bile acid administration on the relative bioavailability of cyclosporin","volume":"29","author":"Lindholm","year":"1990","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2024103013284438600_cit29","first-page":"43S","article-title":"Pharmacokinetics and bioavailability of midazolam in man","volume":"16","author":"Heizmann","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"2024103013284438600_cit30","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1124\/jpet.103.061671","article-title":"Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat","volume":"309","author":"Matsubara","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"2024103013284438600_cit31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejps.2009.01.006","article-title":"Comparison of effects of VDR versus PXR, FXR and GR ligands on the regulation of CYP3A isozymes in rat and human intestine and liver","volume":"37","author":"Khan","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"2024103013284438600_cit32","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0090-9556(25)07487-2","article-title":"Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450","volume":"24","author":"Ghosal","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"2024103013284438600_cit33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/(SICI)1099-081X(199901)20:1<49::AID-BDD158>3.0.CO;2-5","article-title":"Pharmacokinetics and electroencephalographic effects of ketoconazole in the rat","volume":"20","author":"Kotegawa","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"2024103013284438600_cit34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0022-3565(25)12795-X","article-title":"Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation","volume":"277","author":"Gentile","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"2024103013284438600_cit35","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0024-3205(98)00440-8","article-title":"Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats","volume":"63","author":"Watanabe","year":"1998","journal-title":"Life Sci"},{"key":"2024103013284438600_cit36","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/A:1023433502647","article-title":"Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate","volume":"20","author":"Tolle-Sander","year":"2003","journal-title":"Pharm Res"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.2042-7158.2010.01176.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/63\/1\/58\/60234667\/j.2042-7158.2010.01176.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/63\/1\/58\/60234667\/j.2042-7158.2010.01176.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T21:39:50Z","timestamp":1740692390000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/63\/1\/58\/6135462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1,1]]},"published-print":{"date-parts":[[2011,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.2042-7158.2010.01176.x","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"type":"electronic","value":"2042-7158"},{"type":"print","value":"0022-3573"}],"subject":[],"published-other":{"date-parts":[[2011,1]]},"published":{"date-parts":[[2011,1,1]]}}}